Sironax
@sironax.com
Sironax is a clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory, immunologic, and metabolic diseases. Founded in 2017, the company has built a diverse pipeline of programs by targeting contributors of aging, degeneration, metabolic dysfunction, and inflammation. Sironax is conducting clinical studies with SARM1 inhibitor SIR2501, NAMPT activator SIR4156, and RIPK1 inhibitor SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups. For more information, visit sironax.com.
Sironax's Company Logos
Sironax's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#00A3A4
Persian Green
0, 163, 164
180, 100, 32
100, 1, 0, 36
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#0E1231
Haiti
14, 18, 49
233, 56, 12
71, 63, 0, 81
About Sironax
Company type
Privately Held
Year founded
2017
Company size
51-200 employees
